Abstract

Context: Platelet-rich fibrin (PRF) is a 2nd generation platelet concentrate. It contains high levels of growth factors (GF) and is used to treat various diseases. Aims: To estimate the concentrations of Platelet-derived growth factor (PDGF) and Vascular endothelial growth factor (VEGF) in PRF and to compare them in different age groups. Settings and Design: Samples were collected randomly from 28 healthy subjects. Subjects were divided into 2 groups: Group A - 18 to 27 years and group B - 28 to 65 years. Methods and Material: PRF preparation - 10 ml of whole blood was collected without anticoagulant and was centrifuged at 700 g for 12 minutes. The PRF clot was formed in the middle of the tube. The PRF clot was then centrifuged at 10,000 g for 15 minutes for obtaining the PRF releasate and was frozen at - 800C. Estimation of PDGF and VEGF was done using ELISA method and were evaluated. Statistical analysis used: Descriptive statistics like mean, median, standard deviation and ranges were calculated. An unpaired t-test was used to compare Group A and Group B. Results: The mean concentrations of both growth factors were higher in group A. The difference in the concentration of VEGF was statistically significant (P Value - 0.0478). Conclusions: A major advantage of PRF is its autologous nature. However, the concentrations of these two growth factors were higher in the younger age group which supports the use of allogeneous PRF in treatment of older patients. Key Messages: Considering the higher growth factor concentration in the younger age group, this study may influence our opinion towards using allogenic PRF for therapy in the older population. However, a larger case control investigation is necessary to substantiate the findings.

• 1.   Kumar, Vinay;Abbas, Abul K;Aster JC. Robbins Basic Pathology. 10th ed. Kumar, Vinay; Abbas, Abul K;Aster JC, editor. Elsevier - Health Sciences Division; 2021.
• 2.   Khiste SV, Naik Tari R. Platelet- Rich Fibrin as a Biofuel for Tissue Regeneration. ISRN Biomater. 2013;2013:1–6.
• 3.   Su CY, Kuo YP, Tseng YH, Su CH, Burnouf T. In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology [Internet]. 2009;108(1):56–61. Available from: http://dx.doi.org/10.1016/j.tripleo.2009.02.004.
• 4.   Anilkumar K, Geetha A, Umasudhakar, Ramakrishnan T, Vijayalakshmi R, Pameela E. Platelet-rich- fibrin: A novel root coverage approach. J Indian Soc Periodontol. 2009;13 1):50.
• 5.   Cortese A, Pantaleo G, Borri A, Caggiano M, Amato M. Platelet-rich fibrin (PRF) in implant dentistry in combination with new bone regenerative technique in elderly patients. Int J Surg Case Rep [Internet]. 2016;28:52–6. Available from: http://dx.doi.org/10.1016/j.ijscr.2016.09.022.
• 6.   Vaheb M, Karrabi M, Khajeh M, Asadi A, Shahrestanaki E, Sahebkar M. Evaluation of the Effect of Platelet-Rich Fibrin on Wound Healing at Split-Thickness Skin Graft Donor Sites: A Randomized, Placebo-Controlled, Triple-Blind Study. Int J Low Extrem Wounds. 2021;20(1):29–36.
• 7.   Nishimoto S, Fujita K, Sotsuka Y, Kinoshita M, Fujiwara T, Kawai K, et al. Growth Factor Measurement and Histological Analysis in Platelet Rich Fibrin: A Pilot Study. J Maxillofac Oral Surg. 2015;14(4):907–13.
• 8.   Judith R, Nithya M, Rose C, Mandal AB. Application of a PDGF-containing novel gel for cutaneous wound healing. Life Sci. 2010;87(1–2):1–8.
• 9.   Nistér M, Enblad P, Bäckström G, Söderman T, Persson L, Heldin CH, et al. Platelet-derived growth factor (PDGF) in neoplastic and non-neoplastic cystic lesions of the central nervous system and in the cerebrospinal fluid. Br J Cancer. 1994;69(5):952.

Data Sharing Statement

Funding